Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Capital Employed (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Return on Capital Employed data on record, last reported at 20.16% in Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 2258.0% year-over-year to 20.16%; the TTM value through Sep 2025 reached 20.16%, up 2258.0%, while the annual FY2024 figure was 1.99%, 46.0% down from the prior year.
  • Return on Capital Employed reached 20.16% in Q3 2025 per BTAI's latest filing, down from 43.17% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 43.17% in Q2 2025 and bottomed at 4.12% in Q1 2025.
  • Average Return on Capital Employed over 4 years is 3.27%, with a median of 2.39% recorded in 2024.
  • Peak YoY movement for Return on Capital Employed: plummeted -204bps in 2023, then soared 4552bps in 2025.
  • A 4-year view of Return on Capital Employed shows it stood at 0.83% in 2022, then plummeted by -246bps to 2.87% in 2023, then fell by -9bps to 3.14% in 2024, then skyrocketed by 741bps to 20.16% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 20.16% in Q3 2025, 43.17% in Q2 2025, and 4.12% in Q1 2025.